Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

<p>Shows the persistence of anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) in the peripheral blood of two out of four patients.</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Ulka N. Vaishampayan (15051039) (author)
Altres autors:	Archana Thakur (15051042) (author), Wei Chen (15051045) (author), Abhinav Deol (15051048) (author), Meera Patel (15051051) (author), Kimberlee Dobson (15051054) (author), Brenda Dickow (15051057) (author), Dana Schalk (15051060) (author), Amy Schienschang (15051063) (author), Sarah Whitaker (15051066) (author), Amanda Polend (15051069) (author), Joseph A. Fontana (411960) (author), Elisabeth I. Heath (15024674) (author), Lawrence G. Lum (15051072) (author)
Publicat:	2025
Matèries:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
per: Ulka N. Vaishampayan (15051039)
Publicat: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
per: Ulka N. Vaishampayan (15051039)
Publicat: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
per: Ulka N. Vaishampayan (15051039)
Publicat: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
per: Giuseppe Basile (15051269)
Publicat: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
per: Roger Li (17078665)
Publicat: (2025)

Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
per: H. Josh Jang (15206898)
Publicat: (2025)

Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
per: Zachary Quinn (15052893)
Publicat: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
per: Ruiyun Zhang (17142498)
Publicat: (2025)

Supplement 4 from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
per: Fei Cao (22247259)
Publicat: (2025)

Figure 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
per: John Powderly (15026168)
Publicat: (2025)

Figure 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
per: John Powderly (15026168)
Publicat: (2025)

Figure 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
per: John Powderly (15026168)
Publicat: (2025)

Figure S1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
per: John Powderly (15026168)
Publicat: (2025)

Figure S2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
per: John Powderly (15026168)
Publicat: (2025)

Table 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
per: John Powderly (15026168)
Publicat: (2025)

Table 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
per: John Powderly (15026168)
Publicat: (2025)

Table 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
per: John Powderly (15026168)
Publicat: (2025)

Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
per: Bunpei Isoda (22273897)
Publicat: (2025)

Figure 2 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
per: Bunpei Isoda (22273897)
Publicat: (2025)

Figure 3 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
per: Bunpei Isoda (22273897)
Publicat: (2025)

Table 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
per: Bunpei Isoda (22273897)
Publicat: (2025)

Table 2 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
per: Bunpei Isoda (22273897)
Publicat: (2025)

Table 3 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
per: Bunpei Isoda (22273897)
Publicat: (2025)

Table 4 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
per: Bunpei Isoda (22273897)
Publicat: (2025)

Supplemental Table 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
per: Bunpei Isoda (22273897)
Publicat: (2025)

Figure 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
per: Robert W. Lentz (17013559)
Publicat: (2025)

Figure 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
per: Robert W. Lentz (17013559)
Publicat: (2025)

Figure 3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
per: Robert W. Lentz (17013559)
Publicat: (2025)

Figure 4 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
per: Robert W. Lentz (17013559)
Publicat: (2025)

Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
per: Robert W. Lentz (17013559)
Publicat: (2025)

Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
per: Robert W. Lentz (17013559)
Publicat: (2025)

Supplementary Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
per: Robert W. Lentz (17013559)
Publicat: (2025)

Supplementary Table 3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
per: Robert W. Lentz (17013559)
Publicat: (2025)

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
per: Diwakar Davar (15023480)
Publicat: (2025)

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
per: Diwakar Davar (15023480)
Publicat: (2025)

Figure 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
per: Diwakar Davar (15023480)
Publicat: (2025)

Table 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
per: Diwakar Davar (15023480)
Publicat: (2025)

Table 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
per: Diwakar Davar (15023480)
Publicat: (2025)

Table 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
per: Diwakar Davar (15023480)
Publicat: (2025)

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
per: Diwakar Davar (15023480)
Publicat: (2025)